Ephedrine Alkaloid AERs Release Without FDA Analysis Urged By SBA

Release of a negative FDA analysis with recent adverse event reports on ephedrine alkaloid-containing dietary supplements "could eliminate the market for these products without FDA ever needing to continue its rulemaking," the Small Business Administration says in a March 17 letter to the agency.